- Home
- FLYX vs PRLD Comparison
FLYX vs PRLD Comparison
Compare FLYX & PRLD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLYX
- PRLD
- Stock Information
- Founded
- FLYX 2015
- PRLD 2016
- Country
- FLYX United States
- PRLD United States
- Employees
- FLYX N/A
- PRLD N/A
- Industry
- FLYX Blank Checks
- PRLD Medicinal Chemicals and Botanical Products
- Sector
- FLYX Finance
- PRLD Health Care
- Exchange
- FLYX Nasdaq
- PRLD Nasdaq
- Market Cap
- FLYX 39.4M
- PRLD 44.0M
- IPO Year
- FLYX N/A
- PRLD 2020
- Fundamental
- Price
- FLYX $3.72
- PRLD $0.89
- Analyst Decision
- FLYX
- PRLD Strong Buy
- Analyst Count
- FLYX 0
- PRLD 3
- Target Price
- FLYX N/A
- PRLD $4.00
- AVG Volume (30 Days)
- FLYX 24.6K
- PRLD 133.9K
- Earning Date
- FLYX 08-13-2025
- PRLD 08-14-2025
- Dividend Yield
- FLYX N/A
- PRLD N/A
- EPS Growth
- FLYX N/A
- PRLD N/A
- EPS
- FLYX N/A
- PRLD N/A
- Revenue
- FLYX $347,746,000.00
- PRLD $7,000,000.00
- Revenue This Year
- FLYX $28.47
- PRLD N/A
- Revenue Next Year
- FLYX $22.44
- PRLD N/A
- P/E Ratio
- FLYX N/A
- PRLD N/A
- Revenue Growth
- FLYX 17.09
- PRLD N/A
- 52 Week Low
- FLYX $1.79
- PRLD $0.61
- 52 Week High
- FLYX $4.90
- PRLD $5.95
- Technical
- Relative Strength Index (RSI)
- FLYX 71.36
- PRLD 52.78
- Support Level
- FLYX $2.70
- PRLD $0.75
- Resistance Level
- FLYX $4.00
- PRLD $0.96
- Average True Range (ATR)
- FLYX 0.36
- PRLD 0.09
- MACD
- FLYX 0.18
- PRLD 0.01
- Stochastic Oscillator
- FLYX 84.79
- PRLD 67.87
About FLYX flyExclusive Inc.
flyExclusive Inc is an owner and operator of curated private aviation experiences dedicated to surpassing passenger expectations for quality, convenience, and safety. Its mission is to be the world's majority vertically integrated private aviation company through capital-efficient program growth, an industry pricing model, optimal dispatch availability, in-house training, and a controlled premium customer experience on modernized aircraft. The company has over 100 aircraft in its owned and leased fleet which includes light, midsize, super-midsize, and large jets. As one of the nation's Citation operators, it has curated a versatile fleet of Citation CJ3/CJ3 plus, Citation Excel/XLS/XLS plus, Citation Encore/Encore plus, Citation Sovereign, and Citation X aircraft.
About PRLD Prelude Therapeutics Incorporated
Prelude Therapeutics Incorp is a clinical stage precision oncology company focused on discovering and developing small molecule therapies optimized to target the key driver mechanisms in cancers with high unmet needs. The company's pipeline includes four candidates currently in clinical development: PRT1419, a potent, selective inhibitor of MCL1; PRT2527, a potent and selective CDK9 inhibitor, PRT3645, a next-generation CDK4/6 inhibitor, and PRT3789 a first-in-class SMARCA2/BRM protein degrader.